Patents by Inventor Kazuto Nishio
Kazuto Nishio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240314901Abstract: A light source device includes light sources, a light output unit, optical filters, temperature sensors detecting current temperatures of the sources, light quantity sensors detecting current light quantities of light beams before traveling through the filters, a storage, and a processor. The storage stores first correlation information between the temperatures of the sources and spectral information and second correlation information between the spectral information and light quantity of light at the unit. The processor is configured to calculate a variation in the spectral information based on each current temperature and the first information, calculate a variation in the light quantity of the light at the unit caused by a change in the spectral information based on the variation in the spectral information and the second information, and calculate a light-quantity correction amount for each of the sources based on the variation in the light quantity and the current light quantity.Type: ApplicationFiled: May 30, 2024Publication date: September 19, 2024Applicant: OLYMPUS MEDICAL SYSTEMS CORP.Inventors: Koji MATSUMOTO, Masahiro NISHIO, Kazuto FUJIWARA
-
Patent number: 11879150Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient would be advantageous. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.Type: GrantFiled: September 23, 2016Date of Patent: January 23, 2024Assignees: YAKULT HONSHA CO., LTD., KINKI UNIVERSITYInventors: Kazuto Nishio, Yoshihiko Fujita
-
Publication number: 20190002988Abstract: The present invention relates to a RET fusion gene such as a CCDC6-RET fusion gene as a biomarker to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments. The present invention also relates to specific uses of said specific compound in the treatment of cancers.Type: ApplicationFiled: December 5, 2016Publication date: January 3, 2019Inventors: Hidetoshi HAYASHI, Kazuhiko NAKAGAWA, Kazuto NISHIO, Kunio OKAMOTO, Kazuko SAKAI, Toshio SHIMIZU, Masayuki TAKEDA, Kaoru TANAKA
-
Publication number: 20180285521Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient has not been available. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.Type: ApplicationFiled: September 23, 2016Publication date: October 4, 2018Applicants: YAKULT HONSHA CO., LTD., KINKI UNIVERSITYInventors: Kazuto NISHIO, Yoshihiko FUJITA
-
Patent number: 8802384Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.Type: GrantFiled: March 9, 2010Date of Patent: August 12, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Tokuzo Arao, Kanae Kudo, Kazuhiko Nakagawa, Kazuto Nishio
-
Publication number: 20130314526Abstract: Provided is a cell concentration/purification device having a function of successively locating cells in a specific area of a microchannel, and a function of sequentially capturing cell images by use of light from a plurality of monochromatic light sources on an image basis, and performing comparative analysis of the cell images to recognize individual cells based on information on the shape of the cells and an absorption spectral distribution of the cells or inside of the cells, thereby selectively separating/purifying the cells.Type: ApplicationFiled: September 16, 2011Publication date: November 28, 2013Inventors: Kenji Yasuda, Hideyuki Terazono, Hyonchol Kim, Masahito Hayashi, Akihiro Hattori, Kazuto Nishio, Tokuzo Arao, Yohei Miyagi, Takashi Ohtsu
-
Publication number: 20130085081Abstract: Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene.Type: ApplicationFiled: June 8, 2011Publication date: April 4, 2013Applicants: National Cancer Center, Kinki University, Mitsubishi Chemical Medience CorporationInventors: Fumiaki Koizumi, Shintaro Kanda, Tomohide Tamura, Koichi Goto, Masaru Sekijima, Akira Ohide, Kazuto Nishio
-
Patent number: 8372647Abstract: The present invention provides novel markers for diagnosing pancreatic cancer, and methods for determining if a subject has pancreatic cancer utilizing the markers, etc. The methods involve comparing mass-spectrometric peaks of certain sugar chains, obtained from patients' blood and determining if there is a significant decrease in peak intensity, compared with corresponding peaks from patients without pancreatic cancer.Type: GrantFiled: May 8, 2009Date of Patent: February 12, 2013Assignee: Sumitomo Bakelite Company LimitedInventors: Tokuzo Arao, Kazuko Matsumoto, Kazuto Nishio, Hiroki Sakamoto, Masayuki Kitano, Masatoshi Kudo
-
Patent number: 8207357Abstract: An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure. (In chemical formula 1, m?2, n?3, and X represents an anionic molecule or an anionic atom.Type: GrantFiled: October 21, 2009Date of Patent: June 26, 2012Assignees: Wan Station Co., Ltd., Tokyo Institute of Technology, Fukuoka University, Kinki UniversityInventors: Toshikazu Takata, Yasuhito Koyama, Kazuko Nakazono, Toshihide Hasegawa, Young-Gi Lee, Nobufumi Ono, Kazuto Nishio, Yoshihiko Fujita
-
Publication number: 20110237807Abstract: An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure.Type: ApplicationFiled: October 21, 2009Publication date: September 29, 2011Applicants: WAN STATION CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY, FUKUOKA UNIVERSITY, KINKI UNIVERSITYInventors: Toshikazu Takata, Yasuhito Koyama, Kazuko Nakazono, Toshihide Hasegawa, Young-Gi Lee, Nobufumi Ono, Kazuto Nishio, Yoshihiko Fujita
-
Publication number: 20110065141Abstract: The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases.Type: ApplicationFiled: May 8, 2009Publication date: March 17, 2011Applicant: SUMITOMO BAKELITE COMPANY LIMITEDInventors: Tokuzo Arao, Kazuko Matsumoto, Kazuto Nishio, Hiroki Sakamoto, Masayuki Kitano, Masatoshi Kudo
-
Publication number: 20100233705Abstract: The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.Type: ApplicationFiled: March 9, 2010Publication date: September 16, 2010Inventors: Tokuzo ARAO, Kanae KUDO, Kazuhiko NAKAGAWA, Kazuto NISHIO
-
Publication number: 20080286785Abstract: The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.Type: ApplicationFiled: April 7, 2008Publication date: November 20, 2008Applicant: AstraZeneca UK LimitedInventors: Kazuto Nishio, Hideharu Kimura, Kazuo Kasahara
-
Patent number: 6683083Abstract: Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]: wherein R represents: or a pharmaceutically acceptable salt thereof. Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.Type: GrantFiled: August 2, 2002Date of Patent: January 27, 2004Inventors: Noboru Kaneko, Kazuto Nishio